KR101797567B1 - Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina - Google Patents
Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina Download PDFInfo
- Publication number
- KR101797567B1 KR101797567B1 KR1020170039741A KR20170039741A KR101797567B1 KR 101797567 B1 KR101797567 B1 KR 101797567B1 KR 1020170039741 A KR1020170039741 A KR 1020170039741A KR 20170039741 A KR20170039741 A KR 20170039741A KR 101797567 B1 KR101797567 B1 KR 101797567B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- fractions
- extracts
- present
- fraction
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 138
- 230000037303 wrinkles Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 241001082360 Euphorbia supina Species 0.000 title claims abstract description 7
- 241001599881 Euphorbia maculata Species 0.000 title claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 52
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 19
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 19
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 102000029816 Collagenase Human genes 0.000 claims abstract description 18
- 108060005980 Collagenase Proteins 0.000 claims abstract description 18
- 229960002424 collagenase Drugs 0.000 claims abstract description 17
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 12
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000469 ethanolic extract Substances 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 11
- 241001327638 Cimex lectularius Species 0.000 claims description 10
- 240000002853 Nelumbo nucifera Species 0.000 claims description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 23
- 235000013305 food Nutrition 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 abstract description 5
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000004519 manufacturing process Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 239000006071 cream Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- -1 polyoxyethylene Polymers 0.000 description 14
- 238000000605 extraction Methods 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 239000002038 ethyl acetate fraction Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 206010004194 Bed bug infestation Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 239000002036 chloroform fraction Substances 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 239000012223 aqueous fraction Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000131329 Carabidae Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- 241001414835 Cimicidae Species 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 229940096118 ella Drugs 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 241000254032 Acrididae Species 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 240000008886 Ceratonia siliqua Species 0.000 description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000058084 Aegle marmelos Species 0.000 description 1
- 235000003930 Aegle marmelos Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241001668545 Pascopyrum Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물에 관한 것이다. The present invention relates to a composition for preventing or improving skin wrinkles comprising extracts or fractions of a lotus root bed or a bed rock bed as an active ingredient.
나이가 들면 피부노화현상으로 주름이 지게 된다. 피부 노화의 원인은 크게 노령화 등의 내적 요인과 환경적 요인으로 분류할 수 있으며, 생기는 부위에 따라 목주름, 이마주름, 미간주름, 눈밑 잔주름, 입술주위 잔주름, 얼굴 전체에 생기는 미세한 주름 등이 있다. 피부 주름은 진피 내에 있는 콜라겐 섬유의 감소와 변성으로 생긴다. 또, 탄력 섬유의 변성도 피부의 탄력성을 떨어뜨려 피부의 주름을 악화시킨다.When it gets older, it becomes wrinkled due to aging of the skin. The cause of skin aging is largely divided into internal factors such as aging and environmental factors. There are neck wrinkles, forehead wrinkles, fine wrinkles, fine lines around eyes, fine wrinkles around the lips, . Skin wrinkles are caused by the reduction and denaturation of collagen fibers in the dermis. Also, the degeneration of the elastic fibers deteriorates the elasticity of the skin and wrinkles the skin.
대부분 잔주름은 20대 후반에서 30대에 접어들면서 생기기 시작해 웃을 때 점점 뚜렷이 나타나며 40대에 접어들면서 더욱 뚜렷해져 굵은 주름이 된다. 이러한 주름 생성의 예방 및 완화를 위한 광범위한 연구가 발전되면서 피부에 있어서 콜라겐의 중요한 기능들이 밝혀지고 있으며 피부 내 콜라겐의 합성 촉진 및 원천적으로 콜라겐 층의 붕괴를 방지하여 나이가 들며 생기는 피부주름을 억제하고자 하는 연구가 진행되고 있다. Most of the fine wrinkles appear in the late 20s and early 30s. When they are laughing, they become more apparent. When they are in their 40s, they become more pronounced and become thicker wrinkles. As widespread researches for the prevention and alleviation of wrinkle formation have been developed, important functions of collagen have been revealed in the skin. In order to promote the synthesis of collagen in the skin and prevent the collagen layer from collapsing at its origin, Research is underway.
아울러, 환경 요인, 특히 자외선으로부터 유도된 MMPs에 의해 과도하게 기질이 분해되면서 조직의 손상에 의하여 피부 주름이 지게 된다. UVA는 진피의 섬유모세포에서 MMP-1, MMP-2 및 MMP-3의 발현을 유도하며, UVB는 정상 각질형성세포에서 MMP-1, MMP-3 및 MMP-9의 발현을 유도한다. 최근 노화에 따른 MMPs의 증가와 관련된 세포 신호 전달 경로는 주로 MAP (stress-activated mitogen-activated protein) kinase pathway가 관여한다고 보고되어 있다. 따라서, 자외선으로부터 노출된 피부는 MAPK signal을 활성화 시켜, AP-1의 발현을 유도하게 되고, 이러한 과정 중에서 교원질 분해효소인 MMPs의 발현을 증가시켜 콜라겐의 분해와 합성이 감소되면서 반복된 자외선 노출에 의해 주름이 형성된다. In addition, environmental factors, especially MMPs induced from ultraviolet rays, degrade the substrate excessively, resulting in wrinkles of the skin due to tissue damage. UV A shall induce the expression of MMP-1, MMP-2 and MMP-3 in the fibroblasts of the dermis, UV B, induce MMP-1, the expression of MMP-3 and MMP-9 in normal keratinocytes. Recently, it has been reported that MAP (stress-activated mitogen-activated protein) kinase pathway is involved mainly in the signal transduction pathway associated with the increase of MMPs due to aging. Therefore, skin exposed to ultraviolet light activates MAPK signal and induces AP-1 expression. In this process, expression of collagenase MMPs is increased, collagen degradation and synthesis are reduced, and repeated UV exposure A wrinkle is formed.
한편, 큰땅빈대(Euphorbia maculata)는 대극과에 속하는 일년생 초본으로 약간 적자색을 띠고 한쪽 방향으로 짧은 털이 있다. 식물체에 상처가 나면 유약이 나오고 가지는 보통 2개씩 갈라진다. 잎은 마주나며 수평으로 퍼지면서 2줄로 배열한다. 가장자리에 잔 톱니가 있고 표면은 청록색, 뒷면은 회록색이다. 앞바닥이 비대칭하고, 아주 드물게 붉은 반점이 있기도 하다. 꽃은 8~9월에 줄기 끝부분에서 연한 적자색 잔모양 꽃차례로 핀다. 큰땅빈대는 우리나라 전국에 귀화되어 자라고, 유럽, 아시아, 북미 등에 널리 분포되어 있다. On the other hand, the Euphorbia maculata is a perennial herbaceous plant belonging to the major pole and has a slightly reddish purple color and short hairs in one direction. When a plant is scratched, the glaze comes out and branches usually split into two pieces. Leaves are opposite and spread horizontally and arranged in 2 lines. There is a sawtooth on the edge, the surface is cyan, and the back side is green. The front is asymmetrical, and very rarely there are red spots. Flowers bloom from August to September at the end of the stem with a pale purplish red flower. It is widely distributed throughout Europe, Asia, and North America.
또한, 애기땅빈대(Euphorbia supina)는 대극과(Euphorbiaceae)에 속하는 일년생 초본으로, 원줄기는 지면을 따라 퍼지며 길이는 10~25㎝이고, 잎과 더불어 털이 다소 있고, 중앙부에는 붉은빛이 도는 갈색 반점이 있으며 백색의 유액이 함유되어 있다. 잎은 길이 5~10㎜, 너비 4~6㎜의 긴 타원형으로 마주나며 가장자리에 가는 톱니가 있고 수평으로 퍼져서 두 줄로 배열된다. 잎의 윗면은 진한 녹색으로 윤이 나고 뒷면은 녹백색이며, 잎자루는 몹시 짧다. 애기땅빈대는 우리나라와 중국, 일본, 동남아시아, 남북미 등 온대와 열대지방에 널리 분포되어 있다. Euphorbia supina is a perennial herb that belongs to the Euphorbiaceae . Its main stem extends along the ground and is 10 ~ 25㎝ long. There are some hairs with leaves and a reddish brown spot in the center. And white fluid. Leaves are long oval with length of 5 ~ 10㎜ and width of 4 ~ 6㎜, with sawtooth on edge, spread horizontally and arranged in two lines. The upper surface of the leaf is dark green, the back is rusty white, and the petiole is very short. The bedbugs are widely distributed in temperate and tropical regions of Korea, China, Japan, Southeast Asia, and North and South America.
이에 본 발명자들은 천연물인 큰땅빈대 및 애기땅빈대를 활용하여 피부 상태를 개선하기 위하여 다양한 약리효과에 대하여 실험을 수행하던 중 큰땅빈대 및 애기땅빈대의 추출물 및 분획물이 우수한 주름 예방 또는 개선 효과를 가짐을 확인하고 본 발명을 완성하였다. Accordingly, the present inventors conducted experiments on various pharmacological effects in order to improve the skin condition by utilizing the natural land beds and the baby bed beds, while the extracts and fractions of the bed bugs and the bird beds have excellent wrinkle preventing or improving effects And completed the present invention.
본 발명의 목적은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for prevention or improvement of wrinkles containing an extract or fraction of a groundbreaking bed or a bedding bed as an active ingredient.
본 발명의 또다른 목적은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 피부 외용제를 제공하는 것이다.Another object of the present invention is to provide a skin external preparation for preventing or improving wrinkles containing an extract or a fraction of a groundbreaking bed or a baby bed bed as an active ingredient.
상기 과제를 달성하기 위하여, 본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for prevention or improvement of wrinkles comprising extracts or fractions of a lotus leaf bed or a baby bed bed as an active ingredient.
또한, 본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving wrinkles containing extracts or fractions of a lotus bug or a bird bed bug as an active ingredient.
또한, 본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 피부 외용제를 제공한다.In addition, the present invention provides an external preparation for skin for preventing or improving wrinkles containing an extract or a fraction of a ground bed or a bed of a baby as an active ingredient.
본 발명의 큰땅빈대 또는 애기땅빈대의 추출물 및 분획물은 피부 조직 및 이의 탄력과 상관관계가 있는 콜라게네이즈 및 엘라스테이즈를 억제하는 효과를 가지며, 특히 피부 자극에 의하여 주름 발생에 관여하는 것으로 알려진 효소인 MMP-1을 억제하는 효과를 가지고 있어 피부 주름 예방 또는 개선 효과를 가진다. 더욱이 세포 독성을 가지지 않는 바, 본 발명의 큰땅빈대 또는 애기땅빈대의 추출물 및 분획물은 화장료, 식품, 의외약품 등으로 다양하게 활용될 수 있다는 이점이 있다.The extracts and fractions of the present invention are effective for inhibiting collagenase and elastase, which are correlated with skin texture and elasticity thereof. Especially, Has an effect of inhibiting MMP-1, an enzyme, and thus has an effect of preventing or improving wrinkles of the skin. Furthermore, the extract and the fractions of the present invention are not cytotoxic. Therefore, the extracts and fractions of the present invention can be advantageously used as cosmetics, foods, unexpected drugs, and the like.
도 1은 본 발명의 큰땅빈대 추출물 및 분획물을 제조하는 과정을 도식화하여 나타낸 도이다.
도 2는 본 발명의 애기땅빈대 추출물 및 분획물을 제조하는 과정을 도식화하여 나타낸 도이다.
도 3은 큰땅빈대 추출물 및 분획물의 콜라게네이즈(collagenase) 활성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로 도 3a는 큰땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 3b는 큰땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 4는 애기땅빈대 추출물 및 분획물의 콜라게네이즈 활성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로 도 4a는 애기땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 4b는 애기땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 5는 큰땅빈대 추출물 및 분획물의 엘라스테이즈(elastase) 활성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로는 도 5a는 큰땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 5b는 큰땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 6은 애기땅빈대 추출물 및 분획물의 엘라스테이즈 활성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로는 도 6a는 애기땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 6b는 애기땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 7은 MTT 분석을 통한 큰땅빈대 추출물 및 분획물의 세포 독성을 확인한 결과를 나타낸 도이다. 구체적으로 도 7a는 큰땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 7b는 큰땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 8은 MTT 분석을 통한 애기땅빈대 추출물 및 분획물의 세포 독성을 확인한 결과를 나타낸 도이다. 구체적으로 도 8a는 애기땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 8b는 애기땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 9는 ELISA를 통한 큰땅빈대 추출물 및 분획물의 MMP-1 생성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로 도 9a는 큰땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 9b는 큰땅빈대 분획물에 대한 결과를 나타낸 도이다.
도 10은 ELISA를 통한 애기땅빈대 추출물 및 분획물의 MMP-1 생성 억제 효과를 확인한 결과를 나타낸 도이다. 구체적으로 도 10a는 애기땅빈대 추출물에 대한 결과를 나타낸 도이고, 도 10b는 애기땅빈대 분획물에 대한 결과를 나타낸 도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a diagram illustrating the process for preparing the extracts and fractions of the present invention. FIG.
FIG. 2 is a diagram illustrating a process for preparing the extracts and fractions of the present invention.
FIG. 3 is a graph showing the results of confirming the collagenase activity inhibitory effect of the extracts and fractions of the ground beetles. Specifically, FIG. 3A shows the results for the large-scale bandage extract, and FIG. 3B shows the results for the large-scale bandage fraction.
FIG. 4 is a graph showing the results of confirming the collagenase activity inhibitory effect of the extracts and fractions of Arysia thunbergii. Specifically, FIG. 4A is a graph showing the results for a baby bird bed band extract, and FIG. 4B is a chart showing results for a baby bird bed baby fraction.
FIG. 5 is a graph showing the results of confirming the inhibitory effect on the elastase activity of the extracts and fractions of the ground beetles. Specifically, FIG. 5A is a graph showing the results for the large-scale band-pass extract, and FIG. 5B is a graph showing the results for the large-scale band-size fraction.
FIG. 6 is a graph showing the results of confirming the inhibitory effect of the extracts and fractions of Arysia bryophytes on Elastase activity. Specifically, FIG. 6A is a graph showing the results for a baby bird bed band extract, and FIG. 6B is a chart showing results for a baby bird bed baby fraction.
FIG. 7 is a graph showing the cytotoxicity of the extracts and fractions of the poultry passages obtained by MTT analysis. FIG. Specifically, FIG. 7A is a graph showing the results for the large-scale bandage extract, and FIG. 7B is a graph showing the results for the large-sized bandage fraction.
FIG. 8 is a graph showing the cytotoxicity of the extracts and fractions of the rice terra cotta group through MTT analysis. Specifically, FIG. 8A is a graph showing the results for a baby bird bed band extract, and FIG. 8B is a chart showing results for a baby bird bed baby fraction.
FIG. 9 is a graph showing the results of confirming the inhibitory effect of MMP-1 on the extracts and fractions of large-scale beetles by ELISA. Specifically, FIG. 9A is a graph showing the results for the large-scale bandage extract, and FIG. 9B is a graph showing the results for the large-sized bandage fraction.
10 is a graph showing the results of confirming the inhibitory effect of MMP-1 on the extracts and fractions of Pyranididae through ELISA. Specifically, FIG. 10A is a graph showing the results for the baby bird bed band extract, and FIG. 10B is a graph showing the results for the baby bird bed fauna fraction.
본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 조성물을 제공한다.The present invention provides a composition for prevention or improvement of wrinkles comprising extracts or fractions of a lotus bug or a bird bed bug as an active ingredient.
이하 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
일례로 본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 화장료 조성물을 제공한다.For example, the present invention provides a cosmetic composition for prevention or improvement of wrinkles containing an extract or fraction of a groundbreaking bed or a bedding bed as an active ingredient.
본 발명에 있어서, '추출물'은 천연물로부터 어떤 활성 성분을 적당한 용매로 분리한 것을 모두 포함하는 개념으로, 즉, 본 발명에서 사용되는 추출물은 추출 또는 정제의 각 단계에서 얻어지는 모든 추출물 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.In the present invention, the term "extract" is a concept including all kinds of active substances separated from a natural substance by a suitable solvent, that is, the extract used in the present invention is not limited to all the extracts and tablets obtained in each step of extraction or purification, A diluent, a concentrate, or a dried product.
본 발명에 있어서, '분획물'은 상기 추출물에 추가로 적당한 용매를 이용하여 분획한 것을 모두 포함하는 개념이다.In the present invention, the term "fraction" includes not only the extract but also fractions obtained by using a suitable solvent.
본 발명에 있어서, 큰땅빈대 추출물 및 애기땅빈대 추출물은 다양한 수확시기에 수확한 큰땅빈대나 애기땅빈대 및 이의 다양한 부위로부터 추출 또는 분획될 수 있으며, 바람직하게는 가을경에 수확한 큰땅빈대나 애기땅빈대로부터 추출 또는 분획될 수 있다. 또한, 상기 큰땅빈대 추출물 및 애기땅빈대 추출물은 큰땅빈대나 애기땅빈대의 꽃, 잎, 줄기, 뿌리 또는 전초로부터 추출 또는 분획될 수 있고, 바람직하게는 큰땅빈대의 전초, 애기땅빈대의 전초로부터 추출 또는 분획될 수 있으나, 이제 제한되는 것은 아니다. In the present invention, the extracts of the broad-banded and broad-banded grasshopper extracts can be extracted or fractionated from a large number of land harvested at various harvesting times, a terrestrial broad-band and various parts thereof, preferably, Can be extracted or fractionated from the ground bed. In addition, the extracts of the above-mentioned poultice bandages and the poultry parasites can be extracted or fractionated from the flowers, leaves, stems, roots or outposts of the poultry beds or the poultry beds, preferably from the outposts of the poultry beds Extracted or fractionated, but are not limited to these.
상기 추출물 또는 분획물은 당업계에 공지된 추출, 분리 및 분획하는 방법을 사용하여 천연으로부터 추출, 분리 및 분획하여 수득한 것을 사용할 수 있으며, 다양한 추출 또는 분획 용매와 추출 또는 분획 방법에 따라 추출될 수 있다는 것이 특징이다. The extract or fraction may be obtained by extracting, isolating and fractionating the natural extract using a method of extraction, separation and fractionation known in the art, and may be extracted according to various extraction or fractionation solvents and extraction or fractionation methods. .
상기 추출물은 큰땅빈대 또는 애기땅빈대의 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함하며, 그 중에서도 극성용매 가용 추출물인 것이 바람직하다. 더욱이 상기 극성용매 가용 추출물은 물 또는 유기용매, 예를 들어 상기 용매로는 물, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등의 탄소수 1 내지 4의 알코올 등을 단독으로 또는 2종 이상 혼합한 것일 수 있고, 바람직하게는 에탄올이며, 보다 바람직하게는 50 내지 80%의 에탄올일 수 있으며, 가장 바람직하게는 70%의 에탄올일 수 있으나, 이에 제한되는 것은 아니다.The extract may be a crude extract, a polar solvent extract or a non-polar solvent extract, preferably a polar solvent extract. In addition, the polar solvent-soluble extract may be water or an organic solvent such as water, methanol, ethanol, propanol, isopropanol, butanol, 4 alcohol or the like may be used singly or in combination of two or more kinds, preferably ethanol, more preferably 50 to 80% ethanol, most preferably 70% ethanol, But is not limited to.
상기 분획물은 헥산, 클로로포름, 에틸아세테이트, 부탄올, 물 또는 이들의 혼합용매일 수 있으며, 특히 클로로포름, 에틸아세테이트 및 물을 이용하여 순차적으로 분획하여 얻어지는 분획물인 것이 바람직하다.The fraction may be hexane, chloroform, ethyl acetate, butanol, water or a mixture thereof, preferably a fraction obtained by successively fractionating using chloroform, ethyl acetate and water.
본 발명에 있어서, 상기 추출물의 추출 온도는 50~100 ℃인 것이 바람직하나, 이에 제한되지 않는다. 또한 추출방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법이 사용될 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the extraction temperature of the extract is preferably 50 to 100 ° C, but is not limited thereto. Examples of the extraction method include, but are not limited to, a hot water extraction method, a cold extraction method, a reflux cooling extraction method, a solvent extraction method, a steam distillation method, an ultrasonic extraction method, a leaching method and a pressing method.
상기와 같이 물 또는 유기용매를 이용하여 추출물을 얻은 이후에는 당업계에서 알려진 통상의 방법으로 상온에서 냉침, 가열 및 여과하여 액상물을 얻을 수 있으며, 또는 추가로 용매를 증발, 분무건조 또는 동결건조할 수도 있다. 아울러, 상기와 같이 추출된 추출물을 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조할 수도 있다. After the extract is obtained using water or an organic solvent as described above, a liquid material can be obtained by freezing, heating and filtering at room temperature by a conventional method known in the art, or a liquid material can be obtained by further evaporating, spray drying or freeze- You may. In addition, the extract thus obtained may be prepared into a powder state by an additional process such as vacuum distillation, freeze-drying, or spray drying.
또한 본 발명에 있어서, 상기 추출물을 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획으로도 얻을 수 있다.In the present invention, the extract is further purified using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like Or the like.
본 발명에 있어서, '주름'은 피부가 쇠하여 생긴 잔줄을 지칭하는 개념으로, 햇빛을 포함한 다양한 원인에 의하여 진피 속의 콜라겐 섬유, 탄력섬유 등에 변성이 일어나고, 피부 수분이 감소하여 피부의 탄력이 떨어져 피부가 접히게 되면서 주름이 만들어지는 것이 특징이다. 이에 일부 피하 지방이 흡수되어 주름을 더욱 악화시킨다. In the present invention, the term 'wrinkle' refers to a line formed by the breakage of skin. The wrinkles are caused by denatured collagen fibers and elastic fibers in the dermis due to various causes including sunlight, And the wrinkles are formed. Some subcutaneous fat is absorbed and wrinkles are further exacerbated.
본 발명에 있어서, '예방'은 조성물의 투여에 의해 주름 발생을 억제시키거나 주름의 발생을 지연시키는 모든 행위를 의미한다.In the present invention, " prevention " means any action that suppresses the occurrence of wrinkles or delays the occurrence of wrinkles by administration of the composition.
본 발명에 있어서, '개선'은 조성물의 투여에 의해 주름의 개수가 줄거나 피부 표면이 보다 탄력성 있도록 하는 모든 행위를 의미한다.In the present invention, 'improvement' means any action that reduces the number of wrinkles or increases the elasticity of the skin surface upon administration of the composition.
이에 본 발명의 '주름 예방 또는 개선'은 피부가 쇠하여 생긴 잔줄을 억제시키거나 이의 발생을 지연시키고, 피부가 보다 탄력적으로 보이도록 하는 모든 행위를 의미하는 것으로, 본 발명의 큰땅빈대 및 애기땅빈대는 단순한 자외선 노출에 의한 건조, 피부 탄력 약화에 의한 개선 효과 외에도 그 외 발생할 수 있는 다양한 요인들에 의한 콜라겐 또는 엘라스틴의 분해를 억제함으로써 우수한 주름 개선 효과를 가지는 것을 특징으로 한다.Therefore, the 'prevention or improvement of wrinkles' of the present invention means all the actions that inhibit the scarring caused by skin wrinkles, delay the occurrence of skin wrinkles, and make the skin appear more elastic. In the present invention, Is characterized by having an excellent wrinkle-reducing effect by inhibiting decomposition of collagen or elastin due to various factors other than the drying effect by simple ultraviolet ray exposure and the weakening of skin elasticity.
본 발명에 있어서, '화장료 조성물'은 인체의 외관을 아름답게 하는 모든 물건을 포함하는 개념으로, 상기 화장료 조성물은 큰땅빈대 추출물 또는 분획물과 애기땅빈대 추출물 또는 분획물 외에 화장료 조성물에 통상적으로 사용되는 항산화제, 안정화제, 용해화제, 비타민, 안료, 향료 등과 같은 통상적인 보조제 및 담체가 더 포함될 수 있다. 예를 들어, 상기 화장료 조성물에는 글리세린, 부틸렌 글라이콜, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 시트릭산, 판테놀, 스쿠알란, 소듐 시트레이트, 알란토인 등의 보조성분이 추가로 더 포함될 수 있다.In the present invention, the 'cosmetic composition' is a concept including all objects that make the appearance of a human body beautiful. The cosmetic composition may contain an antioxidant such as an antioxidant commonly used in cosmetic compositions, , Stabilizers, solubilizers, vitamins, pigments, perfumes, and the like. For example, the cosmetic composition may further contain an auxiliary component such as glycerin, butylene glycol, polyoxyethylene hardened castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate, allantoin and the like .
본 발명에 있어서, 화장료 조성물은 기본적으로 피부에 도포되는 것이므로, 당업계의 화장료 조성물을 참조하여 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 마스크팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.In the present invention, since the cosmetic composition is basically applied to the skin, it can be made into any formulation conventionally manufactured by referring to the cosmetic composition of the related art. For example, they may be formulated as solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays, But is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritive cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a mask pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는, 담체 성분으로 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 등이 포함될 수 있다. When the formulation of the present invention is a paste, cream or gel, the carrier component includes an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, .
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트, 폴리아미드 파우더 등이 포함될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄, 디메틸 에테르 등의 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like. Particularly in the case of a spray, Propane / butane, dimethyl ether, and the like.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로 용매, 용해화제, 유탁화제 등이 포함될 수 있고, 구체적으로 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜, 소르비탄의 지방산 에스테르 등이 포함될 수 있다.When the formulation of the present invention is a solution or emulsion, the carrier component may include a solvent, a solubilizing agent, an emulsifying agent, and the like. Specific examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid esters of sorbitan, and the like.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로 물, 에탄올, 프로필렌글리콜 등의 액상 희석제; 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르, 폴리옥시에틸렌 소르비탄 에스테르 등의 현탁제; 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가, 트라칸트 등이 포함될 수 있다.When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol, propylene glycol or the like as the carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, trachant, and the like.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는, 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린유도체, 에톡실화 글리세롤 지방산 에스테르 등이 포함될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, it is preferable to use, as the carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, and the like.
일례로, 본 발명은 큰땅빈대 또는 애기땅빈대 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 건강기능식품 조성물을 제공한다.For example, the present invention provides a health functional food composition for prevention or improvement of wrinkles containing as an active ingredient an extract or a fraction of a groundbreaking bed or a baby bedbug.
본 발명에 있어서, '건강기능식품'이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병 방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품으로, 장기적으로 복용하였을 때 인체에 무해하여야 한다.In the present invention, the term 'health functional food' refers to a food group imparted with added value to function or express the function of the food by using physical, biochemical, biotechnological techniques or the like, or a bioactive rhythm control , Which is designed to express the body's controlling function sufficiently for the prevention and restoration of disease, and should be harmless to the human body when taken over a long period of time.
상기 건강기능식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강기능식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The health functional food may include food-acceptable food supplementary additives, and may further include suitable carriers, excipients and diluents conventionally used in the production of health functional foods.
본 발명의 건강기능식품 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 조성물은 원료에 대하여 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the composition may be added as it is, or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 건강기능식품의 예로는 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병 방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계된 식품을 모두 포함한다.There is no particular limitation on the kind of the health functional food. Examples of health functional foods to which the above substances can be added include dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes. And foodstuffs designed to fully express in vivo the function of controlling the body in terms of regulation of bio-defense rhythm of food composition, prevention and recovery of disease, and the like.
상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 식품 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
일례로, 본 발명은 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 유효성분으로 포함하는 주름 예방 또는 개선용 피부 외용제를 제공한다.For example, the present invention provides an external preparation for skin for preventing or improving wrinkles comprising extracts or fractions of a lotus bug or a bird bed bug as an active ingredient.
본 발명에 있어서, 상기 피부 외용제는 상기 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물과 함께 주름의 예방 또는 치료 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다.In the present invention, the external preparation for skin may contain one or more known active ingredients having the effect of preventing or treating wrinkles together with the extract or the fraction of the above-mentioned large-scale bed or the bed of the baby.
본 발명에 있어서, 상기 피부 외용제는 목적하는 신체 부위에 따라 그 제형이 특별히 한정되지 않으며, 당업계의 공지기술을 참조하여 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 액제, 연고제, 크림제, 로션제, 스프레이제, 패취제, 오일제, 왁스제, 유탁액제, 현탁액제, 겔제 또는 에어로졸제 등 형태로 사용될 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the external preparation for skin is not particularly limited in its formulation depending on the desired body part, and may be prepared in any formulation conventionally manufactured by referring to known techniques in the art. For example, it can be used in the form of liquid, ointment, cream, lotion, spray, patch, oil, wax, emulsion, suspension, gel or aerosol.
본 발명에 있어서, 상기 피부 외용제는 통상적인 첨가제, 예를 들어 보존제, 의약 침투를 보조하는 용매, 연고 및 크림의 경우 연화제 등을 포함할 수 있으며, 에탄올 또는 올레일 알코올과 같은 통상적 담체를 함유할 수 있다.In the present invention, the external preparation for skin may contain conventional additives such as a preservative, a solvent for assisting drug penetration, a softening agent for ointment and cream, and a conventional carrier such as ethanol or oleyl alcohol .
본 발명에 있어서, 상기 피부 외용제는 상술한 성분에 한정되지 않고, 필요에 따라 통상의 피부 외용제에 배합되는 다른 성분을 포함할 수 있다. 예를 들어, 유지 성분, 보습제, 에몰리엔트제, 계면활성제, 유기 또는 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 포함할 수 있다.In the present invention, the external preparation for skin is not limited to the above-described components, and may contain other components as required in conventional external preparation for skin. For example, it is possible to use a water-soluble organic solvent such as a preservative, a humectant, an emollient, a surfactant, an organic or inorganic pigment, an organic powder, an ultraviolet absorbent, an antiseptic, a bactericide, an antioxidant, a plant extract, Cold agents, antiperspirants, purified water, and the like.
중복되는 내용은 본 명세서의 복잡성을 고려하여 생락하며, 본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 의미를 갖는 것이다.The redundant contents are taken into consideration in the complexity of the present specification, and terms not otherwise defined herein have the meanings commonly used in the art to which the present invention belongs.
이하, 본 발명의 이해를 돕기 위하여 실시예, 실험예 및 제조예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예, 실험예 및 제조예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예, 실험예 및 제조예에 한정되는 것은 아니다. 본 발명의 실시예, 실험예 및 제조예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.EXAMPLES Hereinafter, examples, experimental examples and production examples will be described in detail to facilitate understanding of the present invention. However, the following Examples, Experimental Examples and Preparation Examples are intended only to illustrate the contents of the present invention, and the scope of the present invention is not limited to the following Examples, Experimental Examples and Production Examples. The embodiments, examples, and examples of the present invention are provided to enable those skilled in the art to more fully understand the present invention.
실시예Example 1. One. 큰땅빈대A great spot 추출물 및 The extract and 분획물의Fraction 제조 Produce
10월경에 수확한 후 공기 중에서 건조시킨 큰땅빈대(Euphorbia maculata, EM) 전초 500g을 환류추출장치를 이용하여 70%(v/v) 에탄올 또는 물로 50~100℃에서 2회 반복 추출하여 큰땅빈대 에탄올 추출물 71.45 g(EMEE, 수율 14.29%) 및 큰땅빈대 물 추출물 152.00 g(EMDE, 수율 30.40%)을 수득하였다. Euphorbia, which was harvested around October and dried in air maculata, EM) 70% of sentinel 500g using reflux extraction assembly (v / v) ethanol, and water extraction was repeated twice at 50 ~ 100 ℃ keunttang chinch ethanol extract of 71.45 g (EMEE, yield 14.29%) and keunttang chinch water 152.00 g of the extract (EMDE, yield 30.40%) was obtained.
이 후 큰땅빈대 분획물을 얻기 위하여 추가적인 분획과정을 거쳤고, 구체적으로는 다음과 같다. 상기에서 얻은 큰땅빈대 에탄올 추출물 50g을 물 500㎖에 녹인 다음, 클로로포름(Chloroform, CHCl3) 층을 분리하는 과정을 3회 반복하였다. 이렇게 얻어진 클로로포름 층을 합하여 감압 농축하여 분말 형태의 큰땅빈대 클로로포름 분획물 7.745g(EMDM, 수율 15.49%)을 얻었다. 이 후 남은 물 층에 에틸아세테이트(ethyl acetate, CH3COOC2H5)를 가하여 상기와 동일한 방법으로 분획하였으며, 감압 농축 후 동결건조하여 분말형태의 큰땅빈대 에틸아세테이트 분획물 12.635g(EMEA, 수율 25.27%)과 물 분획물 17.095g(EMH2O, 수율 34.19%)을 얻었다. 상기 일련의 과정을 도식화하여 도 1에 나타내었다. After this, additional fractionation process was carried out in order to obtain a fraction of a lot of landfill. Specifically, it is as follows. 50 g of ethanol extract obtained from the above-mentioned supernatant was dissolved in 500 ml of water, and the process of separating the chloroform (CHCl 3 ) layer was repeated three times. The chloroform layers thus obtained were combined and concentrated under reduced pressure to obtain 7.745 g (EMDM, yield: 15.49%) of a fraction of a powdery, fine-ground chlo- roform fraction. Ethyl acetate (CH 3 COOC 2 H 5 ) was added to the remaining water layer, and the mixture was fractionated by the same method as above. The filtrate was concentrated under reduced pressure and lyophilized to obtain 12.635 g of a fraction of ethyl acetate fraction in powder form (EMEA, yield 25.27 %) And 17.095 g of a water fraction (EMH 2 O, yield: 34.19%). The above sequence of processes is illustrated in FIG.
실시예Example 2. 2. 애기땅빈대Baby bedbug 추출물 및 The extract and 분획물의Fraction 제조 Produce
10월경에 수확한 후 공기 중에서 건조시킨 애기땅빈대(Euphorbia supina, ES) 전초 250g을 환류추출장치를 이용하여 70%(v/v) 에탄올 또는 물로 50~100℃에서 2회 반복 추출하여 애기땅빈대 에탄올 추출물 60g(ESEE, 수율 24%) 및 애기땅빈대 물 추출물 152.00 g(ESDE, 수율 30.40%)을 수득하였다.After harvesting in October, airborne bedbugs ( Euphorbia supina, ES) 70% of sentinel 250g using reflux extraction assembly (v / v) extraction, ethanol or 2 times with water at 50 ~ 100 ℃ to Arabidopsis land chinch ethanol extract 60g (ESEE, yield 24%) and Arabidopsis land chinch 152.00 g of water extract (ESDE, yield 30.40%) was obtained.
이 후 애기땅빈대 분획물을 얻기 위하여 추가적인 분획과정을 거쳤고, 구체적으로는 다음과 같다. 상기에서 얻은 애기땅빈대 에탄올 추출물 50g을 물 500㎖에 녹인 다음 클로로포름(Chloroform, CHCl3) 층을 분리하는 과정을 3회 반복하였다. 이렇게 얻어진 클로로포름 층을 합하여 감압 농축하여 분말 형태의 애기땅빈대 클로로포름 분획물 9.6g(ESDM, 수율 19.2%)을 얻었다. 이 후 남은 물 층에 에틸아세테이트(ethyl acetate, CH3COOC2H5)를 가하여 동일한 방법으로 분획하였으며, 감압 농축 후 동결건조하여 분말형태의 애기땅빈대 에틸아세테이트 분획물 25.6g(ESEA, 수율 51.2%)과 애기땅빈대 물 분획물 14.8g(ESH2O, 수율 29.6%)을 얻었다. 상기 일련의 과정을 도식화하여 도 2에 나타내었다. After this, additional fractionation process was carried out to obtain the fraction of the landing stage of birds. Specifically, the fractionation process was as follows. 50 g of the ethanol extract obtained from the above-obtained A. tumefaciens was dissolved in 500 ml of water and then the chloroform (CHCl 3 ) layer was separated three times. The chloroform layers thus obtained were combined and concentrated under reduced pressure to obtain 9.6 g (ESDM, yield: 19.2%) of the chloroform fraction of the petioles in powder form. The residue was fractionated by the same method with ethyl acetate (CH 3 COOC 2 H 5 ), concentrated under reduced pressure and lyophilized to obtain 25.6 g (ESEA, yield 51.2%) of the powdery ethyl acetate fraction ) And 14.8 g (ESH 2 O, yield: 29.6%) of the infected groundwater fraction fraction. The above-mentioned series of processes are illustrated in FIG.
실험예Experimental Example 1. One. 콜라게네이즈Collagenase (( collagenasecollagenase ) 활성 억제 효과 확인) Identification of inhibitory activity
1-1. 1-1. 큰땅빈대A great spot 추출물 및 The extract and 분획물의Fraction 콜라게네이즈Collagenase 활성 억제 효과 확인 Identification of the activity inhibition effect
큰땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여 콜라겐을 분해하는 것으로 알려진 콜라게네이즈의 큰땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.In order to confirm the effect of improving the skin wrinkles of the extracts and fractions of the ground beetles, the activity of collagenase, which is known to decompose collagen, was determined by treatment with the extracts and fractions of the locusts.
먼저 실시예 1에서 수득한 큰땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 1에서 수득한 큰땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 4개의 시료를 제조하였다. 한편, 음성대조군에는 상기 추출물 또는 분획물을 처리하지 않았고, 양성대조군에는 상기 추출물 또는 분획물 대신 0.04% 아데노신만을 처리하였다.First, the four-spot samples obtained in Example 1 were dissolved in 5% DMSO to give a total concentration of 40 and 200 μg / ml, respectively. The chloroform fraction, ethyl acetate fraction and water The fractions were dissolved in 5% DMSO to give a total of four samples at concentrations of 20 and 100 μg / ml, respectively. On the other hand, the above-mentioned extract or fraction was not treated in the negative control group, and only 0.04% adenosine was treated in the positive control group instead of the above-mentioned extract or fraction.
이 후 96-웰 플레이트 각각에 상기에 준비한 시료 5 uL를 첨가하였고, 그 외 HCl(0.1 M, pH 7.5) 및 CaCl2(4 mM)에 4-phenylazobenzyloxycarbonyl-Prp-Leu-Gly-Pro-D-Arg(0.3 mg/ml)을 녹인 기질액 12.5 uL와 7.5 uL의 콜라게나제(0.2 mg/ml)를 더 첨가하였다. 이 후 이를 상온 조건에서 20분 동안 배양하였다. 20분이 경과한 후에 25 uL의 6% 시트르산을 넣어 반응을 정지시켰고, 150 uL의 에틸 아세트산을 더 첨가하여 320 nm에서 흡광도를 측정하였다. 그 결과는 도 3에 나타내었다. Thereafter it was added 5 uL of the sample prepared in each of the 96-well plate, or other HCl (0.1 M, pH 7.5) and a CaCl 2 (4 mM) 4- phenylazobenzyloxycarbonyl-Prp-Leu-Gly-Pro-D- 12.5 μL of the substrate solution in which Arg (0.3 mg / ml) was dissolved and 7.5 μL of collagenase (0.2 mg / ml) were further added. Then, it was incubated at room temperature for 20 minutes. After 20 minutes, 25 μL of 6% citric acid was added to stop the reaction, and 150 μL of ethyl acetic acid was further added to measure the absorbance at 320 nm. The results are shown in Fig.
도 3에 나타낸 바와 같이, 본 발명의 유효성분인 큰땅빈대 추출물 및 분획물은 농도 의존적으로 콜라게네이즈 활성을 억제함을 확인하였다. 특히, 큰땅빈대 에탄올 추출물(EMEE)에서 현저한 콜라게네이즈 활성 억제 효과가 나타남을 확인하였다.As shown in Fig. 3, it was confirmed that the extracts and fractions of the locust bean gland, the active ingredient of the present invention, inhibited collagenase activity in a concentration-dependent manner. Especially, it was confirmed that the ethanol extract (EMEE) inhibited the collagenase activity remarkably.
1-2. 1-2. 애기땅빈대Baby bedbug 추출물 및 The extract and 분획물의Fraction 콜라게네이즈Collagenase 활성 억제 효과 확인 Identification of the activity inhibition effect
애기땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여 콜라겐을 분해하는 것으로 알려진 콜라게네이즈의 애기땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.In order to confirm the effect of extracts and fractions on the skin wrinkles, the activity of collagenase, which is known to decompose collagen, was investigated by treatment with the extracts and fractions from the leaves of the baby.
먼저 실시예 2에서 수득한 애기땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 2에서 수득한 애기땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 4개의 시료를 제조하였다. 한편, 음성대조군에는 상기 추출물 또는 분획물을 처리하지 않았고, 양성대조군에는 상기 추출물 또는 분획물 대신 0.04% 아데노신만을 처리하였다. 이 후 사용한 시료만을 달리하여 상기 실험예 1-1과 동일한 방법으로 실험을 실시하였다. 실험 결과는 475 nm 파장에서 흡광도를 측정하였으며, 이는 도 4에 나타내었다. First, a total of four samples were prepared at a concentration of 40 and 200 μg / ml in 5% DMSO, respectively. The chlorophyll fractions obtained in Example 2, the ethyl acetate fraction And water fractions were dissolved in 5% DMSO to prepare a total of four samples at a concentration of 20 μg / ml and 100 μg / ml, respectively. On the other hand, the above-mentioned extract or fraction was not treated in the negative control group, and only 0.04% adenosine was treated in the positive control group instead of the above-mentioned extract or fraction. Experiments were carried out in the same manner as in Experimental Example 1-1, except that the samples used thereafter were different. The absorbance of the test results was measured at a wavelength of 475 nm, which is shown in FIG.
도 4에 나타낸 바와 같이, 본 발명의 유효성분인 애기땅빈대 추출물 및 분획물은 농도 의존적으로 콜라게네이즈 활성을 억제함을 확인하였다. 특히, 애기땅빈대 에탄올 추출물(ESEE)에서 현저한 콜라게네이즈 활성 억제 효과가 나타남을 확인하였다.As shown in FIG. 4, it was confirmed that the extracts and fractions of A. terbinica, an active ingredient of the present invention, inhibited collagenase activity in a concentration-dependent manner. Especially, it was confirmed that the collagenase activity inhibitory effect is remarkably exhibited in the ethanol extract (ESEE).
실험예Experimental Example 2. 2. 엘라스테이즈Ella Stays (( elastaseelastase ) 활성 억제 효과 확인) Identification of inhibitory activity
2-1. 2-1. 큰땅빈대A great spot 추출물 및 The extract and 분획물의Fraction 엘라스테이즈Ella Stays 활성 억제 효과 확인 Identification of the activity inhibition effect
큰땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여, 혈관의 탄력성을 유지하는 물질인 엘라스틴을 분해하는 효소인 엘라스테이즈의 큰땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.In order to confirm the effect of improving the skin wrinkles of the extracts and fractions of the big belly, the change of the activity of Elastesis, an enzyme that decomposes elastin, which is a substance that maintains the elasticity of blood vessels, was examined by treatment with the extracts of the big belly band and fractions.
먼저, 실시예 1에서 수득한 큰땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 1에서 수득한 큰땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 6개의 시료를 제조하였다. 한편, 음성대조군에는 상기 추출물 또는 분획물을 처리하지 않았고, 양성대조군에는 상기 추출물 또는 분획물 대신 10 ㎍/㎖의 올레아놀산(oleanolic acid)만을 처리하였다.First, the four-spot samples obtained in Example 1 were dissolved in 5% DMSO to give a concentration of 40 and 200 μg / ml, respectively. The chloroform fraction, ethylacetate fraction and ethyl acetate fraction obtained in Example 1 The water fractions were dissolved in 5% DMSO to prepare a total of six samples at concentrations of 20 and 100 μg / ml, respectively. On the other hand, the above-mentioned extract or fraction was not treated in the negative control group, and only 10 μg / ml of oleanolic acid was used as a positive control instead of the above extract or fraction.
이 후 96-웰 플레이트에 각각에 상기에 준비한 시료 40 uL를 첨가하였고, 그 외 트리스-HCL 버퍼(50 mM)에 녹여 2.5 U/ml 농도의 돼지 췌장 엘라스테이즈(procine pancrase elastase) 40 uL와 트리스-HCL 버퍼(50 mM)에 녹여 만든 0.5 mg/ml 농도의 N-succinyl-(L-Ala)3-p-nitroanilide 80 uL을 더 첨가하였다. 이 후 37 ℃ 온도의 조건에서 30분 동안 배양하였다. 30분이 경과한 후, 생성되는 p-니트로아닐리드(p-nitroanilide)량을 확인하기 위하여 445 nm의 파장에서 흡광도를 측정하였다. 그 결과는 도 5에 나타내었다.Then, 40 μL of the above-prepared sample was added to each of the 96-well plates, and further dissolved in Tris-HCL buffer (50 mM), and 40 μL of a 2.5 μl / well pork pancreas elastase And 80 uL of N-succinyl- (L-Ala) 3-p-nitroanilide at a concentration of 0.5 mg / ml prepared by dissolving in 50 mM Tris-HCl buffer was further added. Then, the cells were incubated at 37 DEG C for 30 minutes. After 30 minutes, the absorbance was measured at a wavelength of 445 nm to confirm the amount of p-nitroanilide produced. The results are shown in Fig.
도 5에 나타낸 바와 같이, 본 발명의 유효성분인 큰땅빈대 추출물 및 분획물은 농도 의존적으로 엘라스테이즈 활성을 억제함을 확인하였다. 특히, 큰땅빈대 에탄올 추출물(EMEE)에서 현저한 엘라스테이즈 활성 억제 효과가 나타남을 확인하였다.As shown in FIG. 5, it was confirmed that the extracts and fractions of the locust bean gland, which are the active ingredients of the present invention, inhibit the activity of Elastase in a concentration-dependent manner. Especially, It was confirmed that the extract (EMEE) showed a remarkable inhibitory effect on the activity of Elastase.
2-2. 2-2. 애기땅빈대Baby bedbug 추출물 및 The extract and 분획물의Fraction 엘라스테이즈Ella Stays 활성 억제 Active inhibition
애기땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여 혈관의 탄력성을 유지하는 물질인 엘라스틴을 분해하는 효소인 엘라스테이즈의 애기땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.In order to confirm the skin wrinkle improving effect of the extracts and fractions of the rice terraces, the activity of Elastinase, an enzyme which decomposes elastin, which is a substance that maintains the elasticity of blood vessels,
먼저, 실시예 2에서 수득한 애기땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 2에서 수득한 애기땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 6개의 시료를 제조하였다. 한편, 음성대조군에는 상기 추출물 또는 분획물을 처리하지 않았고, 양성대조군에는 상기 추출물 또는 분획물 대신 10 ㎍/㎖의 올레아놀산(oleanolic acid)만을 처리하였다. 이 후 사용한 시료만을 달리하여 상기 실험예 2-1과 동일한 방법으로 실험을 실시하였다. 실험 결과는 475 nm에서 흡광도를 측정하였으며, 이는 도 6에 나타내었다. First, the baby terrestrial band extract obtained in Example 2 was dissolved in 5% DMSO to prepare a total of four samples at a concentration of 40 and 200 μg / ml, respectively. The baby groundbottom chloroform fraction obtained in Example 2, ethyl acetate Fractions and water fractions were dissolved in 5% DMSO to prepare a total of six samples at concentrations of 20 and 100 μg / ml, respectively. On the other hand, the above-mentioned extract or fraction was not treated in the negative control group, and only 10 μg / ml of oleanolic acid was used as a positive control instead of the above extract or fraction. Experiments were carried out in the same manner as in Experimental Example 2-1, except that the samples used thereafter were different. The absorbance at 475 nm was measured and shown in FIG.
도 6에 나타낸 바와 같이, 본 발명의 유효성분인 애기땅빈대 추출물 및 분획물은 농도 의존적으로 엘라스테이즈 활성을 억제함을 확인하였다. 특히, 애기땅빈대 에탄올 추출물(ESEE)에서 현저한 엘라스테이즈 활성 억제 효과가 나타남을 확인하였다.As shown in FIG. 6, it was confirmed that the extracts and the fractions of the present invention, which are the active ingredients of the present invention, inhibit Elastase activity in a concentration-dependent manner. Especially, it was confirmed that the ethanol extract (ESEE) showed a remarkable inhibitory effect on the activity of Elastase activity.
실험예Experimental Example 3. 3. MTTMTT 분석을 통한 세포 독성 확인 Cytotoxicity through analysis
3-1. 3-1. 큰땅빈대A great spot 추출물 및 The extract and 분획물의Fraction 세포 독성 확인 Cytotoxicity check
MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 분석을 통한 큰땅빈대 추출물 및 분획물의 세포 독성을 확인하였다. 이를 위하여 먼저, 미국세포주은행으로부터 멜라닌세포주를 공급받았고, 이 후 이를 10%의 소 태아 혈청 및 1%의 페니실린이 첨가된 DMEM(Dulbecco's Modified Eagle's Medium)배지에서 배양하였다. 이 후 상기 세포를 실험 수행 전까지 37℃ 온도 및 5% CO2 조건에서 배양하였으며 2회 이상의 계대배양을 거쳐 세포를 안정화시켰다.MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide) analysis was performed to confirm the cytotoxicity of the extracts and fractions. For this purpose, melanocytes were firstly supplied from the American Cell Line Bank and then cultured in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal bovine serum and 1% penicillin. Then, the cells were cultured at 37 ° C and 5% CO 2 until the experiment, and the cells were stabilized by subculturing at least two times.
이 후에는 실시예 1에서 수득한 큰땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 1에서 수득한 큰땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 6개의 시료를 제조한 후 이 기술분야에서 일반적으로 사용되는 MTT 분석법과 동일한 방식으로 실험을 수행하였다. 모든 실험 과정은 기준 시료 및 샘플을 3세트로 실험하였으며, 음성대조군에는 상기 추출물 또는 분획물을 처리하지 않았다. 이 후 실험 결과는 하기 수학식 1에 따라 계산하여 도 7에 나타내었다. Thereafter, the whole lotus band extract obtained in Example 1 was dissolved in 5% DMSO to prepare a total of four samples at a concentration of 40 and 200 μg / ml, respectively. The chloroform fraction and ethyl acetate fraction obtained in Example 1 And water fractions were dissolved in 5% DMSO to prepare a total of six samples at a concentration of 20 μg / ml and 100 μg / ml, respectively, and the experiment was carried out in the same manner as the MTT assay generally used in this technical field. All experimental procedures were run with three sets of reference and samples, and the negative control did not contain the extract or fraction. The results of the experiment are shown in FIG. 7 according to the following equation (1).
도 7에 나타낸 바와 같이, 본 발명의 큰땅빈대 추출물 및 분획물은 고농도에서도 세포 독성을 나타내지 않음을 확인하였다. 이는 본 발명의 큰땅빈대 추출물 및 분획물은 화장료뿐만 아니라 약품 또는 식품 등으로 생체에 투여될 수 있는 안전한 물질임을 나타낸다. As shown in FIG. 7, it was confirmed that the extracts and fractions of the present invention did not show cytotoxicity even at a high concentration. This indicates that the extracts and fractions of the present invention are safe substances that can be administered to living bodies as well as cosmetics as well as drugs and foods.
3-2. 3-2. 애기땅빈대Baby bedbug 추출물 및 The extract and 분획물의Fraction 세포 독성 확인 Cytotoxicity check
MTT 분석을 통한 애기땅빈대 추출물 및 분획물의 세포 독성을 확인하였다. 사용한 시료는 실시예 2에서 수득한 애기땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 제조한 총 4개의 시료와 실시예 2에서 수득한 애기땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 제조한 총 6개의 시료를 사용한 것 외에는 상기 실험예 3-1에서 사용한 세포를 사용하여 동일한 방식으로 실험을 수행하였다. 그 결과는 도 8에 나타내었다.MTT assay was performed to determine the cytotoxicity of the extracts and fractions of A. niger. The used samples were obtained by dissolving the baby grasshopper extract obtained in Example 2 in 5% DMSO to give a total of 4 samples prepared at a concentration of 40 and 200 / / ml, respectively, and the baby groundbottom chloroform fractions obtained in Example 2, ethyl acetate The fractions and water fractions were dissolved in 5% DMSO to give a total of six samples prepared at a concentration of 20 and 100 μg / ml, respectively. Experiments were carried out in the same manner using the cells used in Experimental Example 3-1. The results are shown in Fig.
도 8에 나타낸 바와 같이, 본 발명의 애기땅빈대 추출물 및 분획물은 고농도에서도 세포 독성을 나타내지 않음을 확인하였다. 이는 본 발명의 애기땅빈대 추출물 및 분획물은 화장료뿐만 아니라 약품 또는 식품 등으로 생체에 투여될 수 있는 안전한 물질임을 나타낸다. As shown in FIG. 8, it was confirmed that the extracts and fractions of the present invention did not show cytotoxicity even at a high concentration. This indicates that the present invention is a safe substance that can be administered to a living body as well as cosmetics as well as medicines or foods.
실험예Experimental Example 4. ELISA(enzyme-linked immunosorbent assay)를 통한 4. Through enzyme-linked immunosorbent assay (ELISA) MMPMMP -1(matrix -1 (matrix metalloproteinasemetalloproteinase -1) 생성 억제 효과 확인-1) production inhibitory effect
4-1. 4-1. 큰땅빈대A great spot 추출물 및 The extract and 분획물의Fraction MMPMMP -1 생성 억제 효과 확인-1 production inhibitory effect
큰땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여, ELISA를 수행하여 피부 주름 발생에 관여하는 단백질분해효소인 MMP-1의 큰땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.In order to confirm the effect of extracts and fractions on skin wrinkles, ELISA was performed to examine the activity of MMP-1, a protease involved in the development of skin wrinkles, on the treatment of a large-scale bandage extract and fractions.
먼저 실시예 1에서 수득한 큰땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 1에서 수득한 큰땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 6개의 시료를 제조하였다. 이 후 CCD-986sk 세포(ATCC CRL-1947)를 96-웰 플레이트에 1×104 cell/웰로 분주하고 37℃의 온도 및 5% CO2 조건에서 24시간 동안 안정화시킨 후, 상기 10개의 시료를 각각 처리하였다. 처리 후 48시간이 경과한 후에 MMP-1 ELISA 키트(ENZO, BML-AK404-0001)에서 제공하는 항체를 이용하여 이 기술분야에서 ELISA를 수행하는 통상적인 방식으로 MMP-1의 활성을 측정하였다. 그 결과는 도 9에 나타내었다.First, the four-spot samples obtained in Example 1 were dissolved in 5% DMSO to give a total concentration of 40 and 200 μg / ml, respectively. The chloroform fraction, ethyl acetate fraction and water The fractions were dissolved in 5% DMSO to give a total of six samples at concentrations of 20 and 100 μg / ml, respectively. Subsequently, CCD-986sk cells (ATCC CRL-1947) were dispensed in 96-well plates at 1 × 10 4 cells / well and stabilized at 37 ° C. and 5
도 9에 나타낸 바와 같이, 본 발명의 큰땅빈대 추출물 및 분획물이 MMP-1 활성을 감소시킴을 확인하였다. 특히, 큰땅빈대 에탄올 추출물(EMEE)에서 현저한 MMP-1 활성 억제 효과가 나타남을 확인하였다. 이는 큰땅빈대 추출물 및 분획물이 외부 자극으로 대표되는 TNF-α로 증가된 MMP-1 활성이 억제되어 피부 주름 발생을 억제 및 개선하는 효과를 가짐을 나타낸다. As shown in FIG. 9, it was confirmed that the extracts and fractions of the present invention reduced MMP-1 activity. In particular, it was confirmed that the ethanol extract (EMEE) inhibited the MMP-1 activity remarkably. This indicates that the extracts and fractions of the big belly band inhibit the increase of MMP-1 activity by TNF-a, which is represented by external stimuli, thereby suppressing and improving wrinkles of the skin.
4-2. 4-2. 애기땅빈대Baby bedbug 추출물 및 The extract and 분획물의Fraction MMPMMP -1 생성 억제 효과 확인-1 production inhibitory effect
애기땅빈대 추출물 및 분획물의 피부 주름 개선 효과를 확인하기 위하여, ELISA를 수행하여 피부 주름 발생에 관여하는 단백질분해효소인 MMP-1의 애기땅빈대 추출물 및 분획물 처리에 따른 활성 변화를 확인하였다.To investigate the effect of extracts and fractions on the skin wrinkles, we performed ELISA to examine the activity of MMP-1, a proteolytic enzyme involved in the development of skin wrinkles, upon treatment with the extracts and fractions of Pyranididae.
먼저 실시예 2에서 수득한 애기땅빈대 추출물을 5% DMSO에 녹여 각각 40, 200㎍/㎖의 농도로 총 4개의 시료를 제조하고, 실시예 2에서 수득한 애기땅빈대 클로로포름 분획물, 에틸아세테이트 분획물 및 물 분획물을 5% DMSO에 녹여 각각 20, 100㎍/㎖의 농도로 총 6개의 시료를 제조하였다. 이 후 상기 사용한 시료 외에는 실험예 4-1에서 수행한 방식과 동일하게 실험을 수행하였다. 그 결과는 도 10에 나타내었다.First, a total of four samples were prepared at a concentration of 40 and 200 μg / ml in 5% DMSO, respectively. The chlorophyll fractions obtained in Example 2, the ethyl acetate fraction And water fractions were dissolved in 5% DMSO to prepare a total of six samples at concentrations of 20 and 100 μg / ml, respectively. Thereafter, the experiment was carried out in the same manner as in Experimental Example 4-1 except for the above-mentioned samples. The results are shown in Fig.
도 10에 나타낸 바와 같이, 본 발명의 애기땅빈대 추출물 및 분획물이 MMP-1 활성을 감소시킴을 확인하였다. 특히, 애기땅빈대 에탄올 추출물(ESEE)에서 현저한 MMP-1 활성 억제 효과가 나타남을 확인하였다. 이는 애기땅빈대 추출물 및 분획물이 외부 자극으로 대표되는 TNF-α로 증가된 MMP-1 활성이 억제되어 피부 주름 발생을 억제 및 개선하는 효과를 가짐을 나타낸다. As shown in FIG. 10, it was confirmed that the Pyrannus amyloliquefaciens extract and fractions of the present invention reduced MMP-1 activity. In particular, it was confirmed that the ethanol extract (ESEE) inhibits the MMP-1 activity remarkably in the wheat germ of the wheat bran. This indicates that the extracts and fractions of the terrestrial broad-leaved birds have an effect of inhibiting and improving the occurrence of skin wrinkles by inhibiting MMP-1 activity increased by TNF-a, which is represented by external stimuli.
종합적으로, 본 발명의 큰땅빈대 추출물 및 분획물과 애기땅빈대 추출물 및 분획물은 피부 조직 및 이의 탄력과 상관관계가 있는 콜라게네이즈 및 엘라스테이즈를 억제하는 효과를 가지며, 특히 피부 섬유아 세포에서 피부 주름 발생에 관여하는 것으로 알려진 효소인 MMP-1을 억제하는 효과를 가지고 있어 피부 주름 예방 또는 개선 효과를 가진다. 더욱이 세포 독성을 가지지 않는 바, 본 발명의 큰땅빈대 추출물 및 분획물과 애기땅빈대 추출물 및 분획물은 화장료, 식품, 의외약품 등으로 다양하게 활용될 수 있다는 이점이 있다.In general, the extracts and fractions of the ground beetles of the present invention and the extracts and fractions of the beetles of the present invention have the effect of inhibiting collagenase and elastase, which are correlated with the skin tissue and the elasticity thereof, Has an effect of inhibiting MMP-1, an enzyme known to be involved in wrinkle generation, and has an effect of preventing or improving wrinkles of the skin. Furthermore, since the present invention does not have cytotoxicity, the extracts and fractions of the present invention can be widely used as cosmetics, foods, unexpected drugs, and the like.
이하 본 발명의 큰땅빈대 또는 애기땅빈대의 추출물 또는 분획물을 포함하는 화장료 조성물 또는 건강기능식품 조성물의 제제예를 설명하나, 본 발명을 한정하고자 함이 아니고 단지 이를 구체적으로 설명하고자 함이다.Hereinafter, a preparation example of a cosmetic composition or a health functional food composition containing an extract or fraction of a ground bed or a bed of a bird of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.
제제예Formulation example 1. One. 화장료Cosmetics 제제의 제조 Manufacture of pharmaceutical preparations
1-1. 유연화장수 제조-11-1. Flexible longevity manufacturing -1
큰땅빈대 추출물 또는 분획물 0.1중량%, 1,3-부틸렌글리콜 5.2중량%, 올레일알코올 1.5중량%, 에탄올 3.2중량%, 폴리솔베이트 20 3.2중량%, 벤조페논-9 2.0중량%, 카르복실비닐폴리머 1.0중량%, 글리세린 3.5중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 유연화장수를 제조하였다.0.1% by weight of the extracts or fractions of the big belies, 5.2% by weight of 1,3-butylene glycol, 1.5% by weight of oleyl alcohol, 3.2% by weight of ethanol, 3.2% by weight of
1-2. 유연화장수 제조-21-2. Flexible longevity manufacturing -2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 1-2와 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 1-2 was carried out, except that the extract was used in place of the lotus root extract or fraction, and the extract was used.
1-3. 1-3. 밀크로션Milk lotion 제조-1 Manufacturing-1
큰땅빈대 추출물 또는 분획물 0.1중량%, 글리세린 5.1중량%, 프로필렌글리콜 4.2중량%, 토코페릴아세테이트 3.0중량%, 유동파라핀 4.6중량%, 트리에탄올아민 1.0중량%, 스쿠알란 3.1중량%, 마카다미아너트오일 2.5중량%, 폴리솔베이트 60 1.6중량%, 솔비탄세스퀴롤레이트 1.6중량%, 프로필파라벤 0.6중량%, 카르복실비닐폴리머 1.5중량%, 미량의 향, 미량의 방부제, 잔량의 정제수를 혼합하여 통상의 방법으로 밀크로션을 제조하였다.0.1% by weight of extracts or fractions, glycerin 5.1%, propylene glycol 4.2%, tocopheryl acetate 3.0%, liquid paraffin 4.6%, triethanolamine 1.0%, squalane 3.1%, macadamia nut oil 2.5% , 1.6% by weight of
1-4. 1-4. 밀크로션Milk lotion 제조-2 Manufacturing-2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 1-3과 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 1-3 was carried out except that the extract was used in place of the broad-bandage extract or fraction, and the extract was used.
1-5. 영양크림 제조-11-5. Nourishing Cream Maker -1
큰땅빈대 추출물 또는 분획물 0.5중량%, 글리세린 4.0중량%, 바셀린 3.5중량%, 트리에탄올아민 2.1중량%, 유동파라핀 5.3중량%, 스쿠알란 3.0중량%, 밀납 2.6중량%, 토코페릴아세테이트 5.4중량%, 폴리솔베이트 60 3.2중량%, 카르복실비닐폴리머 1.0중량%, 솔비탄세스퀴올레이트 3.1중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 영양크림을 제조하였다.The composition of the present invention was as follows: 0.5% by weight of the extract or fractions of Wheatgrass, 4.0% by weight of glycerin, 3.5% by weight of petroleum jelly, 2.1% by weight of triethanolamine, 5.3% by weight of liquid paraffin, 3.0% by weight of squalane, 2.6% by weight of beeswax, A nutritional cream was prepared by mixing 3.2 wt% of
1-6. 영양크림 제조-21-6. Nutrition Cream Manufacture -2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 1-5와 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 1-5 was carried out, except that the extract was used in place of the broad-bandage extract or fraction, and the extract was used.
1-7. 마사지크림 제조-11-7. Massage Cream Manufacture -1
큰땅빈대 추출물 또는 분획물 0.5중량%, 글리세린 4.0중량%, 바셀린 3.5중량%, 트리에탄올아민 0.5중량%, 유동파라핀 24.0중량%, 스쿠알란 3.0중량%, 밀납 2.1중량%, 토코페릴아세테이트 0.1중량%, 폴리솔베이트 60 2.4중량%, 카르복실비닐폴리머 1.0중량%, 솔비탄세스퀴올레이트 2.3중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 마사지크림을 제조하였다. , 0.5% by weight of glycerin, 3.5% by weight of petroleum jelly, 0.5% by weight of triethanolamine, 24.0% by weight of liquid paraffin, 3.0% by weight of squalane, 2.1% by weight of beeswax, 0.1% by weight of tocopheryl acetate, A massage cream was prepared by mixing 2.4 wt% of
1-8. 마사지크림 제조-21-8. Massage cream manufacturing -2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 1-7과 동일한 방법으로 실시하였다. 잔량의 정제수를 혼합하여 통상의 방법으로 마사지크림을 제조하였다. The same procedure as in Preparation Example 1-7 was carried out except that the extract was used in place of the broad-leaved extract or fraction, and the extract was used. The remaining amount of purified water was mixed to prepare a massage cream by a conventional method.
1-9. 세정용 1-9. For cleaning 바디클렌저Body Cleanser 제조-1 Manufacturing-1
큰땅빈대 추출물 또는 분획물 1g, 음이온계면활성제 18g, 비이온계면활성제 5g, 글리세린 7g, 소듐클로라이드 3g, 천연올리브액상비누 1.5g, 향료 1g 및 물 100g을 혼합하여 통상의 방법으로 세정용 바디클렌저를 제조하였다. A cleansing body cleanser was prepared in a conventional manner by mixing 1 g of an extract or fractions of anions, 18 g of an anionic surfactant, 5 g of a nonionic surfactant, 7 g of glycerin, 3 g of sodium chloride, 1.5 g of natural olive liquid soap, Respectively.
1-10. 세정용 1-10. For cleaning 바디클렌저Body Cleanser 제조-2 Manufacturing-2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 1-9와 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 1-9 was carried out, except that the extract was used in place of the broad-bandage extract or fraction, and the extract was used.
제제예Formulation example 2. 식품 제제의 제조 2. Manufacture of food preparation
2-1. 건강식품 제조-12-1. Health food manufacturing -1
큰땅빈대 추출물 또는 분획물 100㎎, 비타민 혼합물 적량, 비타민 A 아세테이트 70g, 비타민 E 1.0㎎, 비타민 B1 0.13㎎, 비타민 B2 0.15㎎, 비타민 B6 0.5㎎, 비타민 B12 0.2g, 비타민 C 10㎎, 비오틴 10g, 니코틴산아미드 1.7㎎, 엽산 50g, 판토텐산 칼슘 0.5㎎, 무기질 혼합물 적량, 황산제1철 1.75㎎, 산화아연 0.82㎎, 탄산마그네슘 25.3㎎, 제1인산칼륨 15㎎, 제2인산칼슘 55㎎, 구연산칼륨 90㎎, 탄산칼슘 100㎎ 및 염화마그네슘 24.8㎎을 혼합한 다음, 과립을 제조하고 통상의 방법에 따라 건강식품을 제조하였다. 이때, 상기 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하다.100 mg of Vitamin B acetate, 70 g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of vitamin C, 10 g of biotin, Nicotinic acid amide 1.7 mg,
2-2. 건강식품 제조-22-2. Health food manufacturing -2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 2-1과 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 2-1 was carried out except that the extract was used in place of the extract of Great Wheat Starbucks or the fraction or the fraction obtained from the above-mentioned Example.
2-3. 건강음료 제조-12-3. Health drink manufacturing -1
통상의 건강음료 제조방법에 따라 큰땅빈대 추출물 또는 분획물 100㎎, 비타민 C 15g, 비타민 E(분말) 100g, 젖산철 19.75g, 산화아연 3.5g, 니코틴산아미드 3.5g, 비타민 A 0.2g, 비타민 B1 0.25g, 비타민 B2 0.3g 및 정량의 물을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강음료를 제조하였다. 이때, 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.100 g of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, 0.2 g of vitamin B1 0.25 g, 0.3 g of vitamin B2 and a predetermined amount of water were mixed and heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2L container, sealed sterilized, and refrigerated to prepare a health drink . At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, the mixture ratio may be arbitrarily varied according to the demand, the demanded country, the intended use, and the regional or national preference.
2-4. 건강음료 제조-22-4. Health Drink Manufacturing -2
큰땅빈대 추출물 또는 분획물을 대신하여 애기땅빈대 추출물 또는 분획물을 사용한 것을 제외하고는 상기 제제예 2-2와 동일한 방법으로 실시하였다. The same procedure as in Preparation Example 2-2 was carried out except that the extract was used in place of the broad-bandage extract or fraction, and the extract was used.
Claims (9)
A cosmetic composition for prevention or improvement of wrinkles comprising 70% ethanol extract of Euphorbia maculata or Euphorbia supina as an active ingredient.
상기 큰땅빈대의 추출물은 꽃, 잎, 줄기, 뿌리 및 전초로 이루어진 군으로부터 선택된 1종 이상으로부터 추출되는 것을 특징으로 하는, 주름 예방 또는 개선용 화장료 조성물.
The method according to claim 1,
The cosmetic composition for prevention or improvement of wrinkles according to any one of claims 1 to 3, characterized in that the extract of the above-mentioned lotus leaves is extracted from at least one selected from the group consisting of flowers, leaves, stems, roots and outposts.
상기 애기땅빈대의 추출물은 꽃, 잎, 줄기, 뿌리 및 전초로 이루어진 군으로부터 선택된 1종 이상으로부터 추출되는 것을 특징으로 하는, 주름 예방 또는 개선용 화장료 조성물.
The method according to claim 1,
The cosmetic composition for prevention or improvement of wrinkles according to any one of claims 1 to 3, wherein the extract of the infant bed bug is extracted from at least one selected from the group consisting of flowers, leaves, stems, roots and outposts.
상기 추출물은 핵산, 클로로포름, 에틸아세테이트, 부탄올 및 물로 이루어진 군으로부터 선택된 1종 이상의 용매로 추가적으로 분획되는 것을 특징으로 하는, 주름 예방 또는 개선용 화장료 조성물.
The method according to claim 1,
Wherein the extract is further fractionated with at least one solvent selected from the group consisting of nucleic acid, chloroform, ethyl acetate, butanol and water.
상기 추출물은 50 내지 100 ℃에서 추출되는 것을 특징으로 하는, 주름 예방 또는 개선용 화장료 조성물.
The method according to claim 1,
Wherein the extract is extracted at 50 to 100 占 폚.
상기 추출물은 엘라스타아제, 콜라게네이즈 또는 MMP-1 활성을 억제하는 것을 특징으로 하는, 주름 예방 또는 개선용 화장료 조성물.
The method according to claim 1,
The cosmetic composition for prevention or improvement of wrinkles, wherein the extract inhibits elastase, collagenase or MMP-1 activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170039741A KR101797567B1 (en) | 2017-03-29 | 2017-03-29 | Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170039741A KR101797567B1 (en) | 2017-03-29 | 2017-03-29 | Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101797567B1 true KR101797567B1 (en) | 2017-11-15 |
Family
ID=60387172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170039741A KR101797567B1 (en) | 2017-03-29 | 2017-03-29 | Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101797567B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102038291B1 (en) | 2018-10-05 | 2019-10-30 | 대한민국 | Cosmetic composition comprising extract of Euphorbia supina for improvement of skin damage or skin-protection |
-
2017
- 2017-03-29 KR KR1020170039741A patent/KR101797567B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102038291B1 (en) | 2018-10-05 | 2019-10-30 | 대한민국 | Cosmetic composition comprising extract of Euphorbia supina for improvement of skin damage or skin-protection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR101671852B1 (en) | Skin whitening composition containing extract or fraction of Euphorbia maculata or Euphorbia supina | |
JP5427921B2 (en) | Skin external preparation composition containing rose culture or extract thereof, method for producing the same, functional food, and antioxidant composition | |
KR101797567B1 (en) | Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina | |
KR20200083293A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR102077708B1 (en) | Composition for skin-whitening and anti-winkle comprising extract of Poria cocos, Coix lachrymajobi and Stachys sieboldii fermented using Hericium erinaceum mycelium as effective component | |
KR102386120B1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102139778B1 (en) | Composition for Anti-inflammatory, Skin Whitening, Skin Cell Regeneration, and Anti-Wrinkling Activity Comprising Complex Extract of Plectranthus tomentosa as Active Ingredient | |
KR102379698B1 (en) | A composition for skin whitening or regeneration comprising Melandrium firmum extract | |
KR102212343B1 (en) | Composition for skin anti-aging or moisturization comprising extract of marian plum | |
KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
KR101617198B1 (en) | Skin whitening composition containing keratin peptide | |
KR20170057213A (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
KR102101448B1 (en) | Composition for covering body odor comprising extract of korean fir | |
KR102047461B1 (en) | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof | |
KR101971679B1 (en) | Tyrosinase inhibition and whitening activity of solvent extract of Desmodium sequax Wall or a fraction thereof | |
KR101964837B1 (en) | Composition for improving skin wrinkle comprising Cynomorium songaricum extract or its fraction as effective component | |
KR102275552B1 (en) | Composition for covering body odor comprising extract of colored barley | |
KR20190130543A (en) | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof | |
KR20190089748A (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
KR102534818B1 (en) | Ambrosia trifida supercritical extract and its use | |
KR20150039342A (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
KR102366932B1 (en) | Composition with Antioxidant, Anti-Inflammation, Skin Moisturizing, Anti-Wrinkle, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus Softened Petal as Active Ingredient | |
KR102553245B1 (en) | Composition for antioxidant or inhibiting aging comprising Prunus mume f. viridicalyx extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |